Experimental and Clinical Psychopharmacology

Aims & Scope

Experimental and Clinical Psychopharmacology® publishes advances in translational and interdisciplinary research on psychopharmacology, broadly defined, and/or substance abuse.

The scope of research in these areas continues to expand and to benefit from collaborations across a broad range of disciplines, including behavioral science, biochemistry, brain imaging, genetics, medicine, neuroendocrinology, neuroscience, and pharmacology.

The overall goal of Experimental and Clinical Psychopharmacology is to provide a forum for high-quality, innovative preclinical and clinical research that advances our understanding of the behavioral and biological determinants of the effects of centrally acting drugs.

The journal publishes original reports and brief communications on the development and evaluation of pharmacotherapies for a range of mental health diagnoses, the influence of genetics and hormones on responses to psychoactive drugs, the pharmacological management of pain, and brain imaging studies of the neural correlates of psychoactive drug effects.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.2
2024	2.40

SJR (SCImago Journal Rank)

Year	Value
2024	1.004

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	104

Journal Rank

Year	Value
2024	4795

Journal Citation Indicator

Year	Value
2024	836

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey.

  Citation: 857

  Authors: James C., Lynn A., Ronald C.

• Impulsive and self-control choices in opioid-dependent patients and non-drug-using control patients: Drug and monetary rewards.

  Citation: 598

  Authors: Gregory J., Nancy M., Gary J., Warren K.

• Opioids and the treatment of chronic pain: Controversies, current status, and future directions.

  Citation: 496

  Authors: Andrew, Lisa A., Herman, Russell K.

• Delay discounting of real and hypothetical rewards.

  Citation: 454

  Authors: Gregory J., Andrea M., Bethany R., Lana L.

• A brief history of the development of antidepressant drugs: From monoamines to glutamate.

  Citation: 415

  Authors: Todd M., Joseph H.

• Hyperbolic temporal discounting in social drinkers and problem drinkers.

  Citation: 405

  Authors: Rudy E., Cathy A.

• Impulsivity and rapid discounting of delayed hypothetical rewards in cocaine-dependent individuals.

  Citation: 398

  Authors: Scott F., Gregory D., Michael E., Kathleen T.

• An algorithm for identifying nonsystematic delay-discounting data.

  Citation: 361

  Authors: Matthew W., Warren K.

• The balloon analogue risk task (BART) differentiates smokers and nonsmokers.

  Citation: 331

  Authors: C. W., Will M., Heather A., Jerry B., David R., Christopher W., Jennifer P.

• Craving is associated with smoking relapse: Findings from three prospective studies.

  Citation: 305

  Authors: Joel D., Stephen P.

---